Dren Bio Announces $65 Million Series B Financing To Advance Its Lead Asset Into The Clinic And To Accelerate Development Of New Product Candidates From Its Targeted Myeloid Engager And Phagocytosis Platform
Dren Bio Announces $65 Million Series B Financing To Advance Its Lead Asset Into The Clinic And To Accelerate Development Of New Product Candidates From Its Targeted Myeloid Engager And Phagocytosis Platform
06/14/22, 12:02 PM
Location
foster cityMoney raised
$65 million
Round Type
series b
Dren Bio, Inc. (“Dren Bio” or the “Company”) today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years.
Company Info
Company
Dren Bio
Location
foster city, california, united states